Bubenik, Monica et al. published their research in Journal of Medicinal Chemistry in 2022 | CAS: 25676-75-9

4-Bromo-1-methylimidazole (cas: 25676-75-9) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Reference of 25676-75-9

Identification of RP-6685, an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ was written by Bubenik, Monica;Mader, Pavel;Mochirian, Philippe;Vallee, Frederic;Clark, Jillian;Truchon, Jean-Francois;Perryman, Alexander L.;Pau, Victor;Kurinov, Igor;Zahn, Karl E.;Leclaire, Marie-Eve;Papp, Robert;Mathieu, Marie-Claude;Hamel, Martine;Duffy, Nicole M.;Godbout, Claude;Casas-Selves, Matias;Falgueyret, Jean-Pierre;Baruah, Prasamit S.;Nicolas, Olivier;Stocco, Rino;Poirier, Hugo;Martino, Giovanni;Fortin, Alexanne Bonneau;Roulston, Anne;Chefson, Amandine;Dorich, Stephane;St-Onge, Miguel;Patel, Purvish;Pellerin, Charles;Ciblat, Stephane;Pinter, Thomas;Barabe, Francis;El Bakkouri, Majida;Parikh, Paranjay;Gervais, Christian;Sfeir, Agnel;Mamane, Yael;Morris, Stephen J.;Black, W. Cameron;Sicheri, Frank;Gallant, Michel. And the article was included in Journal of Medicinal Chemistry in 2022.Reference of 25676-75-9 This article mentions the following:

DNA polymerase theta (Polθ) is an attractive synthetic lethal target for drug discovery, predicted to be efficacious against breast and ovarian cancers harboring BRCA-mutant alleles. Here, we describe our hit-to-lead efforts in search of a selective inhibitor of human Polθ (encoded by POLQ). A high-throughput screening campaign of 350,000 compounds identified an 11 micromolar hit, giving rise to the N2-substituted fused pyrazolo series, which was validated by biophys. methods. Structure-based drug design efforts along with optimization of cellular potency and ADME ultimately led to the identification of RP-6685 (I): a potent, selective, and orally bioavailable Polθ inhibitor that showed in vivo efficacy in an HCT116 BRCA2-/- mouse tumor xenograft model. In the experiment, the researchers used many compounds, for example, 4-Bromo-1-methylimidazole (cas: 25676-75-9Reference of 25676-75-9).

4-Bromo-1-methylimidazole (cas: 25676-75-9) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Reference of 25676-75-9

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem